Skip to main content
SleepCited

Kava for Hyperarousal and Cognitive Insomnia

A

Based on 23 studies (4 meta-analyses, 1 RCT) with 2,043 total participants. Results are mixed across studies.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'ingredient\u003Dkava\u0026condition\u003Dhyperarousal\u002Dinsomnia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

The Bottom Line

Based on 23 studies (4 meta-analyses, 1 RCT) with 2,043 total participants. Results are mixed across studies.

Key Study Findings

Case Reports n=1 6 weeks
Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption.
Dose: None vs: None Outcome: acute kava dermopathy with sebaceous gland necrosis Effect: None None

Population: 41-year-old Australian woman consuming kava for anxiety and insomnia

Case Reports n=1 Open-label
Severe kava withdrawal managed with phenobarbital.
Dose: None vs: None Outcome: Resolution of kava withdrawal symptoms Effect: None None

Population: 45-year-old man with kava and kratom withdrawal

Other Double-blind
The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and …
Dose: AB-free kava extract vs: Placebo Outcome: Tobacco cessation via stress/insomnia management Effect: None None

Population: Adult smokers (trial protocol)

Controlled Clinical Trial
Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain.
Dose: None vs: Vehicle control Outcome: Acute oral toxicity, antinociceptive activity Effect: None None

Population: Animal model

Systematic Review
The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review.
Dose: None vs: None Outcome: Sleep quality improvement Effect: None None

Population: Insomnia patients

Review
Calm Down With Kava: What Clinicians Need to Know.
Dose: None vs: None Outcome: None Effect: None None

Population: Kava users

Key Statistics

23

Studies

2043

Participants

Mixed

A

Grade

Referenced Papers

The American journal … 2025 1 citations
Journal of psychosocial … 2022 2 citations
Combinatorial chemistry & … 2021 16 citations
Chemical research in … 2019 6 citations
Journal of medicinal … 2018 19 citations
Sleep medicine reviews 2015 152 citations
Advances in pharmacological … 2011 79 citations
Integrative cancer therapies 2004 59 citations
Human psychopharmacology 2003 45 citations
Phytotherapy research : … 2001 74 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Commonly Used Dosages

sleep:
120-250 mg kavalactones/day, 1-2 hrs before bed

Upper limit: 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use

Dosages Studied in Research

Dosage Duration Effect N
None 6 weeks Negative 1
None -- Positive 1
AB-free kava extract -- Mixed --
None -- Positive --
None -- Mixed --
None -- Mixed --
None -- Mixed --
not specified -- Positive --

Best taken: 1-2 hours before bed; avoid daily use beyond 3 months without medical supervision

Safety & Side Effects

Reported Side Effects

  • Drowsiness and reduced coordination
  • Hepatotoxicity (rare but serious — consult healthcare provider)
  • Skin rash (kava dermopathy) with chronic high-dose use
  • GI discomfort

Known Interactions

  • Alcohol — increased hepatotoxicity risk and CNS depression
  • Hepatotoxic medications (acetaminophen, statins) — additive liver stress
  • Benzodiazepines and sedatives — additive CNS depression
  • CYP450 substrates (2E1, 1A2, 2D6) — kavalactones may inhibit metabolism
  • Levodopa and dopaminergic drugs — kava may reduce efficacy

Tolerable upper intake: 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use

Always consult your healthcare provider before starting any supplement.

Frequently Asked Questions

Does Kava help with Hyperarousal and Cognitive Insomnia?
Based on 23 studies with 2,043 participants, there is strong evidence from multiple clinical trials that Kava may support Hyperarousal and Cognitive Insomnia management. Our evidence grade is A (Strong Evidence).
How much Kava should I take for Hyperarousal and Cognitive Insomnia?
Studies have used various dosages. A commonly studied range is 120-250 mg kavalactones/day, 1-2 hrs before bed. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Kava?
Reported side effects may include Drowsiness and reduced coordination, Hepatotoxicity (rare but serious — consult healthcare provider), Skin rash (kava dermopathy) with chronic high-dose use, GI discomfort. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Kava and Hyperarousal and Cognitive Insomnia?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 23 peer-reviewed studies with 2,043 total participants. The overall direction of effect is mixed.

Related Evidence

Other ingredients for Hyperarousal and Cognitive Insomnia

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.